歌禮制藥-B(01672.HK)在第61屆歐洲糖尿病研究協會(EASD)年會上報告其ASC30口服小分子GLP-1R激動劑28天多劑量遞增研究隊列1和隊列2的結果
格隆匯9月17日丨歌禮制藥-B(01672.HK)宣佈,在2025年9月16日在奧地利維也納舉行的第61屆歐洲糖尿病研究協會(EASD)年會上的簡短口頭討論專場會議A中報告了其ASC30口服小分子GLP-1受體(GLP-1R)激動劑28天多劑量遞增(MAD)研究(NCT06680440)隊列1和隊列2的結果。
該Ib期MAD研究是一項在美國開展的隨機、雙盲、安慰劑對照的研究,旨在評估ASC30每日一次口服片在肥胖受試者(體重指數(BMI):30-40 kg/m2)中的安全性與耐受性、不同劑量遞增方案、藥代動力學(PK)特徵及初步療效。
“我們非常高興能在今年EASD年會的口頭報告環節報告ASC30口服片的臨牀數據。”歌禮創始人、董事會主席兼首席執行官吳勁梓博士表示,“ASC30口服片已顯示出優越的療效與安全性數據,這再一次彰顯了我們強大的研發能力,能爲肥胖症治療提供更具差異化的選擇。我們期待在今年第四季度報告ASC30口服片13周IIa期研究的頂線結果。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.